INDUSTRIEPARK ZWIJNAARDE 7, ZWIJNAARDE, C9
Market cap: $44.4B (3/05/2026)
Price: $717.80
To Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
Leading a New Era of Innovation in Immunology
Announces Leadership Transition Marking Next Evolution of Growth
Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
Announces Results of Extraordinary General Meeting of Shareholders
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Free Writing Prospectus
Confidential Treatment Order
Registration Statement for Additional Securities of Certain Foreign Private Issuers, Filed Pursuant to Rule 462(b)